نتایج جستجو برای: hbv core antibody

تعداد نتایج: 390403  

2011
Andrea Costantini Katia Marinelli Giulia Biagioni Alessia Monachetti Monica L Ferreri Luca Butini Maria Montroni Aldo Manzin Patrizia Bagnarelli

BACKGROUND Occult hepatitis B virus (HBV) infection (OBI) is characterized by HBV DNA persistence even though the pattern of serological markers indicates an otherwise resolved HBV infection. Although OBI is usually clinically silent, immunocompromised patients may experience reactivation of the liver disease. CASE PRESENTATION We report the case of an individual with human immunodeficiency v...

Journal: :International Journal of Medical Sciences 2005
Shuping Tong Kyun-Hwan Kim Charles Chante Jack Wands Jisu Li

More than 300 million people worldwide are chronically infected with hepatitis B virus (HBV). Considering the very short generation time for a virus, and the high error rate associated with the reverse transcription step of HBV replication, decades of HBV infection are probably equivalent to million years of human evolution. The most important selective force during the natural course of HBV in...

2015
Nasrin Rastegarvand Manoochehr Makvandi Alireza Samarbafzadeh Mojtaba Rasti Niloofar Neisi Amir Pouremamali Ali Teimoori Abdolnabi Shabani

BACKGROUND Occult hepatitis B infection (OBI) is a major public health problem worldwide, which harbors potential risk of hepatitis B virus (HBV) transmission through blood transfusion and transplantation. OBI is characterized by the presence of HBV-DNA in the blood or liver tissue without detectable hepatitis B surface antigen (HBsAg) in the serum. An important cause of OBI is the occurrence o...

2016
Carla Osiowy Carla Coffin Anton Andonov

There are only two currently approved classes of hepatitis B virus (HBV) antiviral agents, pegylated interferon (Peg-IFN), and nucleos(t)ide analogs (NAs) for chronic HBV infection. Although Peg-IFN is used for a finite 48-week duration and offers a greater chance of sustained off-treatment virological response, it is poorly tolerated and can only be offered to selected patients. The NAs are we...

Journal: :The Indian journal of medical research 2006
A Behzad-Behbahani A Mafi-Nejad S Z Tabei K B Lankarani A Torab A Moaddeb

BACKGROUND & OBJECTIVE Though sensitive screening assays for detection of hepatitis B virus surface antigen (HBsAg) are available, occasional cases of post-transfusion hepatitis B virus infection (PTH) still occur. The present study was undertaken to assess the prevalence of anti-hepatitis B core (anti-HBc) positivity and presence of HBV-DNA in serum sample of healthy blood donors negative for ...

Journal: :reports of biochemistry and molecular biology 0
arezoo honarmand microbiology department, islamic azad university of jahrom, jahrom, iran morteza pourahmad tel: +98 9177916203; fax: +98 7154230021000 kavous solhjoo microbiology department, jahrom university of medical sciences, jahrom, iran mahmoud kohan nursery department, alborz university of medical sciences mohamad hassan davami microbiology department, jahrom university of medical sciences, jahrom, iran seyed kamyar mostafavi zadeh infectious disease department, isfahan university of medical sciences, isfahan, iran

background: in patients who are hepatitis b virus (hbv) dna-positive, but hbv surface antigen (hbsag) -negative, the infection is referred to as occult hepatitis b infection (obi). occult hbv infection is harmful when other liver diseases are present, and can aggravate liver damage in in patients with chronic liver diseases. in human immunodeficiency virus (hiv) infection the suppression of vir...

2015
Stephen Ip Jo-Ann Ford Kirby Lau Vladimir Marquez Marisa Guan Carolyn Klassen Jessica Chan WC Peter Kwan Mel Krajden Eric M Yoshida

BACKGROUND The seroprevalences of hepatitis B virus (HBV) and hepatitis C virus (HCV) are 0.4% and 0.8%, respectively, in Canada, but varying rates have been reported in different populations. OBJECTIVES To determine the seroprevalences of HBV and HCV among attendees of an Asian health fair in the Lower Mainland, British Columbia, as well as to correlate questionnaire answers regarding vaccin...

2015
Atsuya Yamashita Yuusuke Fujimoto Mayumi Tamaki Andi Setiawan Tomohisa Tanaka Kaori Okuyama-Dobashi Hirotake Kasai Koichi Watashi Takaji Wakita Masaaki Toyama Masanori Baba Nicole J. de Voogd Shinya Maekawa Nobuyuki Enomoto Junichi Tanaka Kohji Moriishi Peer B. Jacobson

The current treatments of chronic hepatitis B (CHB) face a limited choice of vaccine, antibody and antiviral agents. The development of additional antiviral agents is still needed for improvement of CHB therapy. In this study, we established a screening system in order to identify compounds inhibiting the core promoter activity of hepatitis B virus (HBV). We prepared 80 extracts of marine organ...

2013
Marilen Queiroz de Souza Alexsandro Sobreira Galdino José Carlos dos Santos Marcus Vinicius Soares Yanna C. de Nóbrega Alice da Cunha Morales Álvares Sonia Maria de Freitas Fernando Araripe Gonçalves Torres Maria Sueli Soares Felipe

Hepatitis B is a liver inflammation caused by hepatitis B virus (HBV) and can be diagnosed in clinical stage by hepatitis B core antibody from IgM class (anti-HBcIgM). Hepatitis B core antibody from IgG class (Anti-HBcIgG) appears quickly after IgM, reaching high titers in chronic hepatitis, and remains even after cure. Since hepatitis B core antibody (anti-HBc) is the first antibody identified...

Journal: :iranian biomedical journal 0
محمد عزیزی mohammad azizi alexis musacchio ornaldo pardo nelvis figueroa verena muzio

dna coding for the core antigen from hepatitis b virus (hbcag) was amplified, cloned and propagated in e. coli. the core protein was expressed in e. coli and the product was readily detected by western blot. this protein can be used as a diagnostic material in serum screening tests. to increase the level of expression of this antigen in bacteria, two plasmids were constructed in which the gene ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید